Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LORATADINE vs ALLEGRA HIVES
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: June 2026 · OpiCalc Medical Review Team
Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1-receptor antagonist activity. It inhibits histamine-induced vasodilation and bronchoconstriction.
Fexofenadine is a non-sedating antihistamine (H1-receptor antagonist) that selectively inhibits peripheral H1 receptors, reducing histamine-mediated symptoms such as pruritus, urticaria, and vasodilation. It does not cross the blood-brain barrier significantly, minimizing CNS effects.
Relief of symptoms of seasonal allergic rhinitis (FDA),Treatment of chronic idiopathic urticaria (FDA),Off-label: adjunctive treatment of allergic conjunctivitis
Relief of symptoms associated with seasonal allergic rhinitis,Treatment of chronic idiopathic urticaria
10 mg orally once daily
Fexofenadine hydrochloride 60 mg orally twice daily or 180 mg orally once daily.
Loratadine: 8-14 hours (mean ~10 hours). Active metabolite descarboethoxyloratadine: 17-24 hours (mean ~20 hours). Clinically, duration supports once-daily dosing.
Terminal elimination half-life is approximately 14.4 hours (range 11–17 hours). This supports once-daily dosing in most patients; however, in moderate to severe renal impairment, half-life may be prolonged (e.g., ~22 hours), necessitating dosing adjustment.
No adjustment required for GFR ≥10 m L/min; avoid use in patients with GFR <10 m L/min due to lack of data
For GFR < 15 m L/min: 60 mg orally once daily. For GFR 15-30 m L/min: 60 mg orally once daily. For GFR > 30 m L/min: no adjustment needed.
Child-Pugh Class A: 10 mg orally once daily; Child-Pugh Class B or C: 10 mg orally every other day
None.
Loratadine is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, and adequate well-controlled studies in pregnant women are lacking. First trimester: no evidence of teratogenicity in epidemiologic studies; second and third trimesters: no known fetal risks.
ALLEGRA HIVES contains fexofenadine hydrochloride. In animal studies, no evidence of teratogenicity was observed at doses up to 3 times the maximum recommended human dose. Human data are limited; however, fexofenadine is not associated with increased risk of major congenital malformations. First trimester: insufficient data but current evidence suggests low risk. Second and third trimesters: no known fetal risks. Fexofenadine is classified as FDA Pregnancy Category C (pre-2015) and is not expected to increase teratogenic risk based on available studies.
Loratadine is a second-generation antihistamine with minimal anticholinergic and sedative effects due to its limited CNS penetration. It is a prodrug that is rapidly converted to its active metabolite desloratadine. Onset of action is within 1-3 hours, and duration is approximately 24 hours. Dose adjustment is recommended for patients with severe hepatic impairment (e.g., Child-Pugh score >10) or renal impairment (Cr Cl <30 m L/min) with a starting dose of 10 mg every other day. It does not interact significantly with CYP3A4 inhibitors like ketoconazole or erythromycin, unlike many other antihistamines. For chronic urticaria, it is first-line therapy. It may be less effective for nasal congestion compared to intranasal corticosteroids.
ALLEGRA HIVES (fexofenadine 180 mg) is a non-sedating antihistamine approved for chronic idiopathic urticaria. Onset of action is within 1 hour; peak effect at 6 hours. Avoid use in severe renal impairment (Cr Cl <30 m L/min) due to increased exposure. May be taken with or without food, but fruit juices (apple, orange, grapefruit) decrease absorption by up to 36%; separate dosing by at least 4 hours.
"The metabolism of Fluvoxamine can be decreased when combined with Loratadine."
"The metabolism of Saquinavir can be decreased when combined with Loratadine."
"The metabolism of Ziprasidone can be decreased when combined with Loratadine."
No interactions on record
Common clinical questions about LORATADINE vs ALLEGRA HIVES, answered by our medical review team.
LORATADINE is a Antihistamine that works by Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1-receptor antagonist activity. It inhibits histamine-induced vasodilation and bronchoconstriction.. ALLEGRA HIVES is a Antihistamine that works by Fexofenadine is a non-sedating antihistamine (H1-receptor antagonist) that selectively inhibits peripheral H1 receptors, reducing histamine-mediated symptoms such as pruritus, urticaria, and vasodilation. It does not cross the blood-brain barrier significantly, minimizing CNS effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LORATADINE and ALLEGRA HIVES depend on the specific clinical indication. These are both Antihistamine agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LORATADINE is: 10 mg orally once daily. The standard adult dose of ALLEGRA HIVES is: Fexofenadine hydrochloride 60 mg orally twice daily or 180 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LORATADINE and ALLEGRA HIVES in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LORATADINE is classified as Category A/B. Loratadine is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, and adequate well-controlled studies in pregnant women are lacking. First tri. ALLEGRA HIVES is classified as Category C. ALLEGRA HIVES contains fexofenadine hydrochloride. In animal studies, no evidence of teratogenicity was observed at doses up to 3 times the maximum recommended human dose. Human da. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.
Loratadine is extensively metabolized in the liver via CYP3A4 and to a lesser extent CYP2D6 to its active metabolite desloratadine.
Fexofenadine undergoes minimal hepatic metabolism; approximately 5% is metabolized by CYP3A4. The majority (up to 95%) is excreted unchanged in feces (80%) and urine (11-12%).
Approximately 40% excreted in urine as metabolites (primarily descarboethoxyloratadine) and 40% in feces as metabolites; <1% excreted unchanged.
Fexofenadine is primarily excreted unchanged in feces (80%) and urine (11%). The remainder undergoes minimal hepatic metabolism. Renal elimination accounts for about 11% of the dose.
Loratadine: 97-99% bound to plasma proteins (albumin and alpha-1-acid glycoprotein). Metabolite: 73-76% bound.
Protein binding is approximately 60–70%, primarily to albumin and alpha1-acid glycoprotein.
Approximately 119 L/kg (range 80-150 L/kg). High Vd indicates extensive tissue distribution, likely due to lipophilicity.
Volume of distribution is 5.4–5.8 L/kg. This relatively high Vd indicates extensive extravascular distribution, consistent with its peripheral antihistamine activity.
Oral bioavailability is high but variable; absolute bioavailability ~70-90% (first-pass metabolism limited).
Oral bioavailability is approximately 25–33% due to incomplete absorption and first-pass metabolism? Actually, fexofenadine has low presystemic metabolism, but absorption is incomplete; bioavailability is about 30% (range 25–33%).
No specific dose adjustment required for hepatic impairment; however, use caution in severe hepatic impairment due to limited data.
2-5 years: 5 mg orally once daily; 6 years and older: 10 mg orally once daily
Children 6 months to <2 years: 15 mg orally twice daily. Children 2-11 years: 30 mg orally twice daily. Children ≥12 years: same as adult dosing.
No specific dose adjustment; use with caution due to potential age-related renal impairment
No specific dose adjustment required; however, elderly patients may be more sensitive to adverse effects. Use lowest effective dose and monitor renal function.
None
No significant food interactions. Loratadine absorption is not affected by food. Grapefruit juice may slightly decrease the active metabolite concentration but this is not clinically significant. Avoid high-fat meals if using the rapidly disintegrating tablet (ODT) as it may reduce absorption. No restriction on alcohol, but caution due to potential additive CNS effects.
Fruit juices (apple, orange, grapefruit) reduce fexofenadine absorption significantly; separate ingestion by at least 4 hours. No other known food interactions.
Loratadine is excreted into human breast milk in low amounts (M/P ratio approximately 1.2). The estimated infant dose is about 1% of the maternal weight-adjusted dose, considered safe for breastfeeding. The American Academy of Pediatrics considers loratadine compatible with breastfeeding.
Fexofenadine is excreted into human breast milk. The milk-to-plasma ratio (M/P) is approximately 0.5. The estimated daily infant dose via breast milk is less than 1% of the maternal weight-adjusted dose, which is considered low. However, caution is advised in lactating women, especially when breastfeeding preterm or low birth weight infants, due to potential anticholinergic effects. Monitor infant for drowsiness, irritability, or feeding difficulties.
No dose adjustment is required during pregnancy. The standard adult dose of 10 mg orally once daily is recommended. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered hepatic metabolism) are not clinically significant for loratadine.
Pregnancy may alter pharmacokinetics of fexofenadine due to increased plasma volume and enhanced renal clearance. However, no specific dose adjustments are recommended by the manufacturer. The standard adult dose of fexofenadine (60 mg twice daily or 180 mg once daily) is considered safe. Monitoring for therapeutic efficacy and adverse effects is advised; no dose reduction is typically needed.
Take one 10 mg tablet or 10 mg oral solution once daily with or without food.,Do not exceed 10 mg in 24 hours; do not take more than directed.,Avoid alcohol consumption as it may increase drowsiness, though loratadine is less sedating than older antihistamines.,If you have severe liver or kidney disease, consult your doctor for dose adjustment.,Store at room temperature away from moisture and heat.,Do not use for rapid relief of acute allergic reactions; seek emergency care for breathing difficulty or throat swelling.,If you miss a dose, skip it and take the next dose at the regular time. Do not double the dose.,Pregnant or breastfeeding patients should consult a healthcare provider before use.,Loratadine may cause dry mouth; sugar-free gum or candy can help.,Children under 2 years of age: do not use without physician advice.,Antihistamines can cause allergic skin rashes rarely; stop use and seek medical attention if you develop hives or swelling.
Take one tablet daily with water, avoiding fruit juices within 4 hours of dosing.,Drowsiness is uncommon but possible; caution with driving if sedated.,Do not exceed one tablet in 24 hours.,Notify your doctor if hives persist after 2 weeks or if symptoms worsen.,Store at room temperature away from moisture and heat.